Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

Abstract EN

Background.

The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D.

Methods.

Treatment consisted of D 30 mg/m2 i.v.

for four consecutive weekly administrations followed by a 2-week rest interval, in addition to Bev 5 mg/kg i.v.

every 2 weeks.

Results.

Forty-three patients were enrolled: a PSA response was observed in 27 patients (62.7%, 95% CI: 0.41 to 0.91), and a palliative response was achieved in 31 patients (72.1%, 95%CI: 0.48 to 1.02).

After a median followup of 11.3 months, only five patients had died.

The regimen was generally well tolerated.

Conclusion.

Weekly D + biweekly Bev seems to be an effective and well-tolerated treatment option for patients with metastatic CRPC previously exposed to D-based chemotherapy.